Literature DB >> 25531913

High-yielding, automated production of 3'-deoxy-3'-[(18)F]fluorothymidine using a modified Bioscan Coincidence FDG reaction module.

Yiu-Yin Cheung1, Michael L Nickels2, Eliot T McKinley3, Jason R Buck2, H Charles Manning4.   

Abstract

INTRODUCTION: High-yielding, automated production of a PET tracer that reflects proliferation, 3'-deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT), is reported using a modified Bioscan Coincidence FDG reaction module.
METHODS: Production of [(18)F]FLT was implemented through: (1) modification of an original FDG manifold; (2) application of an alternate time sequence; and (3) altered solid-phase extraction (SPE) purification. Quality control testing, including standard radiochemical figures of merit and preclinical positron emission tomography (PET) imaging, was carried out.
RESULTS: High decay-corrected yields of [(18)F]FLT (16-39%) were reproducibly obtained. The product exhibited very high specific activity (4586.9TBq/mmol; 123,969Ci/mmol) and radiochemical purity (>99%). Overall, the [(18)F]FLT produced in this manner was superior to typical productions that utilized a GE TRACERlab FXF-N reaction module. Additionally, purification with SPE cartridges, followed by manual elution, accelerated overall run time and resulted in a two-fold increase in [(18)F]FLT concentration. PET imaging showed the [(18)F]FLT produced by this method was highly suitable for non-invasive tumor imaging in mice.
CONCLUSIONS: The Bioscan Coincidence GE FDG Reaction Module was readily adapted to reproducibly provide [(18)F]FLT in high yield, specific activity, and radiochemical purity. The approach was suitable to provide sufficient amounts of material for preclinical studies.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Automated radiosynthesis; Positron emission tomography (PET); Solid-phase extraction (SPE); [(18)F]FLT

Mesh:

Substances:

Year:  2014        PMID: 25531913      PMCID: PMC4867542          DOI: 10.1016/j.apradiso.2014.11.011

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  11 in total

1.  [18F]FLT-PET to predict pharmacodynamic and clinical response to cetuximab therapy in Ménétrier's disease.

Authors:  Eliot T McKinley; R Adam Smith; Jarred P Tanksley; Mary Kay Washington; Ronald Walker; Robert J Coffey; H Charles Manning
Journal:  Ann Nucl Med       Date:  2012-07-22       Impact factor: 2.668

2.  A new precursor for the radiosynthesis of [18F]FLT.

Authors:  S J Martin; J A Eisenbarth; U Wagner-Utermann; W Mier; M Henze; H Pritzkow; U Haberkorn; M Eisenhut
Journal:  Nucl Med Biol       Date:  2002-02       Impact factor: 2.408

3.  Simple and highly efficient synthesis of 3'-deoxy-3'-[18F]fluorothymidine using nucleophilic fluorination catalyzed by protic solvent.

Authors:  Sang Ju Lee; Seung Jun Oh; Dae Yoon Chi; Hee Seup Kil; Euy Nyong Kim; Jin Sook Ryu; Dae Hyuk Moon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-03-24       Impact factor: 9.236

4.  Evaluation of an automated double-synthesis module: efficiency and reliability of subsequent radiosyntheses of FHBG and FLT.

Authors:  Sabrina Niedermoser; Manuela Pape; Franz Josef Gildehaus; Carmen Wängler; Markus Hartenbach; Ralf Schirrmacher; Peter Bartenstein; Björn Wängler
Journal:  Nucl Med Biol       Date:  2011-12-14       Impact factor: 2.408

5.  Efficient radiosynthesis of 3'-deoxy-3'-18F-fluorothymidine using electrowetting-on-dielectric digital microfluidic chip.

Authors:  Muhammad Rashed Javed; Supin Chen; Hee-Kwon Kim; Liu Wei; Johannes Czernin; Chang-Jin C J Kim; R Michael van Dam; Pei Yuin Keng
Journal:  J Nucl Med       Date:  2013-12-23       Impact factor: 10.057

6.  3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer.

Authors:  Eliot T McKinley; R Adam Smith; Ping Zhao; Allie Fu; Samir A Saleh; Md Imam Uddin; M Kay Washington; Robert J Coffey; H Charles Manning
Journal:  J Nucl Med       Date:  2013-01-22       Impact factor: 10.057

7.  Imaging proliferation in vivo with [F-18]FLT and positron emission tomography.

Authors:  A F Shields; J R Grierson; B M Dohmen; H J Machulla; J C Stayanoff; J M Lawhorn-Crews; J E Obradovich; O Muzik; T J Mangner
Journal:  Nat Med       Date:  1998-11       Impact factor: 53.440

8.  Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer.

Authors:  H Charles Manning; Nipun B Merchant; A Coe Foutch; John M Virostko; Shelby K Wyatt; Chirayu Shah; Eliot T McKinley; Jingping Xie; Nathan J Mutic; M Kay Washington; Bonnie LaFleur; Mohammed Noor Tantawy; Todd E Peterson; M Sib Ansari; Ronald M Baldwin; Mace L Rothenberg; Darryl J Bornhop; John C Gore; Robert J Coffey
Journal:  Clin Cancer Res       Date:  2008-11-15       Impact factor: 12.531

9.  Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer.

Authors:  Chirayu Shah; Todd W Miller; Shelby K Wyatt; Eliot T McKinley; Maria Graciela Olivares; Violeta Sanchez; Donald D Nolting; Jason R Buck; Ping Zhao; M Sib Ansari; Ronald M Baldwin; John C Gore; Rachel Schiff; Carlos L Arteaga; H Charles Manning
Journal:  Clin Cancer Res       Date:  2009-07-07       Impact factor: 12.531

10.  Limits of [18F]-FLT PET as a biomarker of proliferation in oncology.

Authors:  Eliot T McKinley; Gregory D Ayers; R Adam Smith; Samir A Saleh; Ping Zhao; Mary Kay Washington; Robert J Coffey; H Charles Manning
Journal:  PLoS One       Date:  2013-03-15       Impact factor: 3.240

View more
  1 in total

1.  18F-FLT Positron Emission Tomography (PET) is a Pharmacodynamic Marker for EWS-FLI1 Activity and Ewing Sarcoma.

Authors:  Christy L Osgood; Mohammed N Tantawy; Nichole Maloney; Zachary B Madaj; Anderson Peck; Elissa Boguslawski; Jennifer Jess; Jason Buck; Mary E Winn; H Charles Manning; Patrick J Grohar
Journal:  Sci Rep       Date:  2016-09-27       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.